Breaking News on Biopharmaceutical Development & Manufacturing

Top Headlines

Breaking the Big Four: vaccine oligopoly unlikely to be challenged, analyst

Long lead times and high barriers to entry will restrict competition in the vaccines market, leaving GSK, Sanofi, Merck & Co. and Pfizer dominant, a Jefferies analyst says.

Bluebird Bio reports positive early safety data from Ph I CAR-T trial

Bluebird Bio has reported encouraging efficacy and safety data from a Phase I trial of its CAR-T multiple myeloma therapy, bb2121.

Valitacell moves into NIBRT lab space to further develop cell lines

Valitacell has moved into the National Institute for Bioprocessing Research and Training (NIBRT) as it works to further develop its cell performance technologies.

News in brief

Arrowhead fires CSO & Co-inventor of delivery tech responsible for clinical trial abandonment

Arrowhead Pharmaceuticals Inc. has also laid off its Chief scientific officer David Lewis - as part of the 34 staff cull - after several trials using delivery vehicle Ex1 were stopped by the firm.

Takeda building Dengue fever vaccine plant

Takeda has started work on a vaccine plant to make its candidate Dengue fever virus vaccine, TAK-003.


Juno deaths: Toxicity is therapy specific, not risk to whole CAR-T field, say experts

The deaths in a trial of Juno Therapeutics’ JCAR015 are most likely product-specific says the CEO of French CAR-T developer TxCell, who rejected the idea that chemotherapy or the CD19 target played a part.

Thermo Fisher buys MTI-GlobalStem upping stem cell and reagent offering

Thermo Fisher has bolstered its stem cell technology and reagent business through the acquisition of MTI-GlobalStem.

Promotional Features

Key Industry Events


Access all events listing

Our events, Shows & Conferences...